Pelthos Therapeutics Inc.

AMEX:PTHS

Biotechnology

Healthcare
$16.54 -1.28%

-$0.37 today

Market cap
$63.32M
Beta
3.13
P/E (TTM)
-0.7
EPS (TTM)
-$15.58
52W Low $16.50High $37.50

Volume 0.01M

Average 0.04M

PTHS EBITDA Margin

EBITDA as a percentage of revenue.

Pelthos Therapeutics Inc.AMEX: PTHS

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin at -58.5%

EBITDA Margin was -58.5% in Q1 FY2026. On a trailing-twelve-month basis it was -181.8%.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 6 analysts of -42.2% for the fiscal year ending Dec 2026, up from -270.4% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-58.5%+219.0 pp QoQ
Last fiscal yearDec 2025
-270.4%— YoY
LTMMar 2026
-181.8%— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year—+228.2 pp—
3 years—+275.1 pp—
5 years+277.7 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-270.4%
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How PTHS compares with its peers on the latest reported figures

PTHS Competitors
EBITDA Margin for PTHS and competitors
Company Period LTM level YoY 3-year change
PTHSPelthos Therapeutics Inc.LTM Mar 2026-181.8% ——
LIXTLixte Biotechnology Holdings, Inc.FY2025— ——
CINGCingulate Inc.FY2025— ——
ENLVEnlivex Therapeutics Ltd.FY2025— ——
Peer median (excluding PTHS) ———

Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000016.8M
Cost of Revenue00009.37M
Gross Profit00007.43M
Gross Margin————44.2%
Research & Development209.05K391.73K2.58M1.18M1.23M
Selling, General & Admin629.95K1.93M4.28M6.39M37.08M
Operating Expenses839K2.32M6.86M7.57M39.86M
Depreciation & Amortization00002.29M
EBITDA(595.13K)(2.32M)(6.86M)(7.17M)(45.41M)
EBITDA Margin————-270.4%
Operating Income(839K)(2.32M)(6.86M)(7.57M)(32.43M)
Operating Margin————-193.1%
Interest Income00005K
Interest Expense253140.43K518.51K786.39K3.01M
Other Income / Expenses243.61K(140.43K)(518.51K)(383.89K)(18.28M)
Income Before Tax(595.39K)(2.46M)(7.38M)(7.96M)(50.71M)
Pre-Tax Margin————-301.9%
Income Tax Expense0000(7.39M)
Net Income(595.39K)(2.46M)(7.38M)(7.96M)(43.32M)
Net Margin————-257.9%
EPS (Basic)(1.00)(4.26)(12.80)(13.54)(23.04)
EPS (Diluted)(1.00)(4.26)(12.80)(13.54)(23.04)
Weighted Avg Shares576.75K576.75K576.75K587.62K1.88M
Weighted Avg Shares (Diluted)576.75K576.75K576.75K587.62K1.88M

Pelthos Therapeutics Inc.

AMEX:PTHS

Intrinsic Alpha fair value

Locked

Current Price

$16.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.